Total Payments
$359,774
2024 Payments
$11,888
Companies
37
Transactions
359
Medicare Patients
2,289
Medicare Billing
$369,251
Payment Breakdown by Category
Other$254,013 (70.6%)
Consulting$62,515 (17.4%)
Research$20,170 (5.6%)
Travel$14,806 (4.1%)
Food & Beverage$7,794 (2.2%)
Education$476.98 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $210,270 | 101 | 58.4% |
| Consulting Fee | $62,515 | 43 | 17.4% |
| Honoraria | $42,949 | 24 | 11.9% |
| Unspecified | $20,170 | 37 | 5.6% |
| Travel and Lodging | $14,806 | 44 | 4.1% |
| Food and Beverage | $7,794 | 102 | 2.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $750.00 | 1 | 0.2% |
| Education | $476.98 | 6 | 0.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $43.36 | 1 | 0.0% |
Payments by Type
General
$339,604
322 transactions
Research
$20,170
37 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $63,059 | 56 | $0 (2024) |
| Jazz Pharmaceuticals Inc. | $45,336 | 29 | $0 (2023) |
| Amgen Inc. | $28,791 | 32 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $23,646 | 17 | $0 (2024) |
| Astellas Pharma US Inc | $20,367 | 21 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $19,561 | 13 | $0 (2024) |
| Kite Pharma, Inc. | $18,043 | 14 | $0 (2021) |
| Agios Pharmaceuticals, Inc. | $15,977 | 15 | $0 (2023) |
| Rigel Pharmaceuticals, Inc. | $15,910 | 13 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $15,877 | 13 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,888 | 19 | Rigel Pharmaceuticals, Inc. ($7,928) |
| 2023 | $41,795 | 39 | Jazz Pharmaceuticals Inc. ($12,790) |
| 2022 | $39,220 | 46 | E.R. Squibb & Sons, L.L.C. ($14,646) |
| 2021 | $33,726 | 37 | Karyopharm Therapeutics Inc. ($7,760) |
| 2020 | $42,669 | 39 | Kite Pharma, Inc. ($8,243) |
| 2019 | $69,012 | 58 | GENZYME CORPORATION ($10,900) |
| 2018 | $60,198 | 53 | Celgene Corporation ($19,796) |
| 2017 | $61,266 | 68 | Celgene Corporation ($30,236) |
All Payment Transactions
359 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $29.79 | General |
| Category: Hematology | ||||||
| 12/12/2024 | Gamida Cell Inc. | OMISIRGE (Biological) | Food and Beverage | In-kind items and services | $43.10 | General |
| Category: ONCOLOGY | ||||||
| 12/08/2024 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $44.71 | General |
| Category: Oncology | ||||||
| 12/07/2024 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | — | In-kind items and services | $225.11 | Research |
| Study: STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY • Category: Oncology | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Education | In-kind items and services | $99.00 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $26.49 | General |
| Category: Oncology | ||||||
| 09/24/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $22.25 | General |
| Category: Oncology | ||||||
| 08/22/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Honoraria | Cash or cash equivalent | $1,713.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 05/30/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Travel and Lodging | Cash or cash equivalent | $11.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 05/16/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,384.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 05/02/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $106.74 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 04/29/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,076.00 | General |
| 04/29/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Honoraria | Cash or cash equivalent | $1,713.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 04/16/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $21.07 | General |
| Category: HEMATOLOGY | ||||||
| 04/05/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $21.70 | General |
| 04/04/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $117.50 | General |
| Category: Oncology | ||||||
| 02/21/2024 | Eurofins Viracor, LLC | — | Food and Beverage | In-kind items and services | $283.14 | General |
| 02/12/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Honoraria | Cash or cash equivalent | $815.00 | General |
| Category: Oncology | ||||||
| 12/15/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: Oncology | ||||||
| 12/11/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $122.76 | General |
| 12/11/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $27.71 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/10/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $38.27 | General |
| 12/09/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $45.05 | General |
| Category: Hematology/Oncology | ||||||
| 12/08/2023 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-4047-MM-014 - Immune profiling of relapsed or refractory multiple myeloma patients treated with pomalidomide and low-dose dexamethasone in combination with daratumumab | Celgene Corporation | $5,914 | 1 |
| CC-4047-MM-014 | Celgene Corporation | $4,881 | 1 |
| A Phase 3 Open-label Multicenter Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. | Astellas Pharma Global Development | $3,146 | 16 |
| Immune profiling of relapsed or refractory multiple myeloma patients treated with pomalidomide and low-dose dexamethasone in combination with daratumumab (CC-4047-MM-014) | Celgene Corporation | $2,916 | 1 |
| A Phase 1 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | Astellas Pharma Global Development | $1,742 | 9 |
| A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. | Astellas Pharma Global Development | $687.97 | 4 |
| CC-4047-MM-007 - Safety and efficacy of pomalidomide, bortezomib, and low-dose dexamethasone in subjects with relapsed or refractory multiple myeloma | Celgene Corporation | $442.00 | 1 |
| STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | Stemline Therapeutics Inc. | $225.11 | 1 |
| Phase 3, Randomized, Multicenter, Open-Label Trial in Asi | Astellas Pharma Global Development | $130.00 | 1 |
| A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation | Astellas Pharma Global Development | $65.50 | 1 |
| A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine After Allogeneic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia (AML) (VIALE-T) | ABBVIE INC. | $19.65 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 535 | 1,550 | $840,204 | $88,417 |
| 2022 | 9 | 594 | 1,629 | $1.1M | $108,398 |
| 2021 | 9 | 640 | 1,653 | $976,189 | $102,958 |
| 2020 | 7 | 520 | 1,434 | $629,985 | $69,478 |
Total Patients
2,289
Total Services
6,266
Medicare Billing
$369,251
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 306 | 1,054 | $535,432 | $55,911 | 10.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 42 | 253 | $118,910 | $17,058 | 14.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 86 | 125 | $107,250 | $7,627 | 7.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 38 | 38 | $41,230 | $4,126 | 10.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 19 | 19 | $6,760 | $1,328 | 19.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 27 | 43 | $15,222 | $1,199 | 7.9% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 17 | 18 | $15,400 | $1,167 | 7.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 221 | 674 | $578,292 | $53,247 | 9.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 199 | 563 | $286,004 | $29,602 | 10.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 28 | 227 | $106,690 | $13,835 | 13.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 45 | 45 | $48,825 | $5,036 | 10.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 21 | 25 | $22,250 | $2,901 | 13.0% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2022 | 21 | 27 | $22,140 | $1,481 | 6.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 17 | 19 | $6,080 | $1,203 | 19.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 29 | 33 | $11,682 | $993.81 | 8.5% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Facility | 2022 | 13 | 16 | $1,572 | $100.33 | 6.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 285 | 866 | $439,928 | $46,121 | 10.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 151 | 343 | $294,294 | $28,607 | 9.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 39 | 249 | $117,030 | $15,458 | 13.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 39 | 39 | $42,315 | $4,455 | 10.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 28 | 29 | $25,810 | $3,315 | 12.8% |
| 38222 | Diagnostic aspirations and biopsies of bone marrow | Facility | 2021 | 32 | 38 | $31,160 | $2,506 | 8.0% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 20 | 21 | $6,720 | $1,321 | 19.7% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 32 | 48 | $16,992 | $1,050 | 6.2% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Facility | 2021 | 14 | 20 | $1,940 | $125.60 | 6.5% |
About Dr. Gary Schiller, MD
Dr. Gary Schiller, MD is a Hematology & Oncology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1851311930.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Schiller, MD has received a total of $359,774 in payments from pharmaceutical and medical device companies, with $11,888 received in 2024. These payments were reported across 359 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($210,270).
As a Medicare-enrolled provider, Schiller has provided services to 2,289 Medicare beneficiaries, totaling 6,266 services with total Medicare billing of $369,251. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Los Angeles, CA
- Active Since 07/20/2006
- Last Updated 06/23/2010
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1851311930
Products in Payments
- VYXEOS (Drug) $45,297
- Revlimid (Drug) $33,966
- XPOVIO (Drug) $23,646
- Pomalyst (Drug) $20,953
- Rezlidhia (Drug) $15,910
- JAKAFI (Drug) $15,693
- XOSPATA (Drug) $15,621
- Kyprolis (Biological) $14,228
- Blincyto (Biological) $13,738
- ISATUXIMAB (Drug) $13,034
- Yescarta (Drug) $12,443
- TIBSOVO (Drug) $11,693
- ELITEK (Drug) $10,900
- REBLOZYL (Biological) $10,822
- ELZONRIS (Drug) $9,915
- NO PRODUCT DISCUSSED (Drug) $7,394
- AYVAKIT (Drug) $6,045
- ONUREG (Drug) $5,876
- Tecartus (Drug) $5,600
- DAURISMO (Drug) $5,410
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Los Angeles
Dennis Slamon, Md, MD
Hematology & Oncology — Payments: $4.3M
Hematology & Oncology $4.3M
George Yaghmour
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Robert Vescio, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Dr. Kevin Kelly, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
David Berz, Md, Phd, Mph, MD, PHD, MPH
Hematology & Oncology — Payments: $613,380
Hematology & Oncology $613,380
Raghuveer Ranganathan, M.d, M.D
Hematology & Oncology — Payments: $472,334
Hematology & Oncology $472,334